Benign, proliferatif ve malign over yüzey epitel tümörlerinde P53, Bcl-2, Ki-67 Li (Labelıng index)

P53, Bcl-2, Ki-67 Li (Labeling Index) status in benign, proliferative, and malignant ovarian surface epithelial neoplasms

Abstract

Objective. Approximately 50% of human malignancies present with mutations in p53, which is the most common tumor suppressor gene involved with human malignancies. Bcl- 2 is a protooncogene, and expression of its protein product is associated with a better prognosis in several malignancies. Ki-67 is a marker of cellular proliferation. The purpose of this study was to determine whether simultaneous detection of p53, bcl-2 and Ki-67 using immunohistochemical staining can be used as a diagnostic factor in the assessment of human ovarian epithelial tumors. Materials and Methods. The study was performed on formalin- fixed, paraffin-embedded tissue samples from 75 epithelial ovarian tumors, 15 serous cystadenomas, 15 mucinous cystadenomas, 5 borderline serous cystadenomas, 5 borderline mucinous cystadenomas, 15 serous cystadenocarcinomas, 15 mucinous cystadenocarcinomas and 5 endometrioid carcinomas. Immunohistochemical staining was performed using monoclonal antibodies against p53, bcl-2, and Ki-67(MIB1).Results. Anti-p53 reactivity was observed in 14 tumors, all of which were malignant tumors, and no reactivity was observed in borderline or benign tumors. Overexpression of bcl- 2 was observed in 12 benign neoplasms (40%), 5 of which were borderline (50%), but was not observed in any of the malignant tumors. There was a statistically significantly higher level of Ki-67 LI positivity in the malignant tumors than in the benign and borderline tumors (p

Özet

Amaç. p53 insan malignesilerinde mutasyonu en sık izlenen tümör baskılayıcı gendir. Bütün kanserlerin %50 sinde izlenir. Bcl-2 ise çeşitli kanserlerde görülen, protein ürünü iyi prognozla ilişkili olan bir protoonkogendir. Ki-67 ise hücre proliferasyon markırıdır. Bu çalışmanın amacı overin epitelyal tümörlerinde immunohistokimyasal çalışma yaparak p53, bcl- 2 ve Ki-67'nin tanıda yerini değerlendirmektir. Gereç ve Yöntem. Bu çalışma; 15 seröz ve müsinöz kistadenom, 15 seröz ve müsinöz kistadenokarsinom, 5 borderline seröz ve müsinöz kistadenom ve 5 endometroid karsinomalı vakalara ait formalin ile fikse parafin bloklarda yapıldı. İmmunohistokimyasal olarak anti-p53, the anti-bcl-2, the anti- Ki-67(MIB1) uygulandı.Bulgular. Anti-p53 aktivitesi bütün malign tümörlerin 14'ünde pozitif olup borderline ve benign tümörlerde boyanma izlenmedi. Bcl-2 overekspresyonu 12 (%40) benign tümörde, 5 (%50) borderline tümörde izlendi fakat malign tümörlerde gözlenmedi. Ki-67 LI ise malign tümörlerde benign ve borderline tümörlere göre istatistik olarak anlamlı daha yüksekti (p